Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms

NCT05315856 · clinicaltrials.gov ↗

UNKNOWN

Status

120

Enrollment

OTHER

Sponsor class

Conditions

COVID-19 Vaccination
Inflammation
Vaccine Immune Response
Vaccine Adverse Reaction

Interventions

BIOLOGICAL: either BNT162b2 or ChAdOx1 vaccine

Sponsor

Korea University Guro Hospital

Collaborators

[object Object]
[object Object]
[object Object]